Increasing unusual option volume: GNS KVUE RYAM FRSH HSBC NVO GES XPOF

Go back to Increasing unusual option volume: GNS KVUE RYAM FRSH HSBC NVO GES XPOF

SELECT trial data a 'significant catalyst' for Novo Nordisk (NVO) - Morgan Stanley

August 22, 2023 11:40 AM EDT

Morgan Stanley analyst Mark Purcell maintained an Overweight rating on Novo Nordisk (NYSE: NVO) in a note Tuesday ahead of the SELECT trial data. The analyst raised the price target on the stock from DKr 1,210 to DKr 1,370 per share.

The analyst told... More